{"DataElement":{"publicId":"6733087","version":"1","preferredName":"Response Assessment Disease Type","preferredDefinition":"A response assessment based on common qualities of any abnormal condition of the body or mind that causes discomfort, dysfunction or distress to the person.","longName":"RESP_ASSESS_DZ_TP","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2012676","version":"3","preferredName":"Response Assessment","preferredDefinition":"Evaluation of a change in the condition under investigation.","longName":"RESPS_ASSESS","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2177008","version":"1","preferredName":"Response","preferredDefinition":"Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"Response","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AD5-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2178813","version":"1","preferredName":"Assessment","preferredDefinition":"The final result of a determination of the value, significance, or extent of.","longName":"Assessment","context":"CCR","contextVersion":"1","Concepts":[{"longName":"Assessment","conceptCode":"C25367","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE26673C-624D-3309-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-12-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-11","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":"Added Concept Code AA","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A56E9E7B-DAEE-1DF9-E034-080020C9C0E0","latestVersionIndicator":"Yes","beginDate":"2002-07-10","endDate":null,"createdBy":"JASUR","dateCreated":"2002-07-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6733022","version":"1","preferredName":"Disease Response Type","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Something distinguishable as an identifiable class based on common qualities._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","longName":"6733022v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"0","maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"CMML Response","valueDescription":"Chronic Myelomonocytic Leukemia Remission","ValueMeaning":{"publicId":"6733023","version":"1","preferredName":"Chronic Myelomonocytic Leukemia Remission","longName":"6733023","preferredDefinition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.: An abatement in intensity or degree (as in the manifestations of a disease).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myelomonocytic Leukemia","conceptCode":"C3178","definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"877037F4-E293-4FCC-E053-F662850A456F","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"SOKKERL","dateModified":"2022-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877037F4-E2AE-4FCC-E053-F662850A456F","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"MDS Response","valueDescription":"Myelodysplastic Syndrome Remission","ValueMeaning":{"publicId":"6733024","version":"1","preferredName":"Myelodysplastic Syndrome Remission","longName":"6733024","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001): An abatement in intensity or degree (as in the manifestations of a disease).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"877037F4-E2BB-4FCC-E053-F662850A456F","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877037F4-E2D6-4FCC-E053-F662850A456F","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"},{"value":"AML Response","valueDescription":"Acute Myeloid Leukemia Remission","ValueMeaning":{"publicId":"6733025","version":"1","preferredName":"Acute Myeloid Leukemia Remission","longName":"6733025","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).: An abatement in intensity or degree (as in the manifestations of a disease).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"877037F4-E2E3-4FCC-E053-F662850A456F","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"877037F4-E2FE-4FCC-E053-F662850A456F","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"ONEDATA","dateModified":"2019-04-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2503462","version":"1","preferredName":"Response Type","preferredDefinition":"In medicine, an improvement related to treatment.:Type; a subdivision of a particular kind of thing.","longName":"C50995:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A0F51C2-CD5A-6923-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-02","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-08-02","modifiedBy":"ONEDATA","dateModified":"2006-08-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"877037F4-E277-4FCC-E053-F662850A456F","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"SOKKERL","dateModified":"2022-11-14","changeDescription":"4/26/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Response Assessment","type":"Preferred Question Text","description":"Response Assessment","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8770BD3C-EDE5-3B5D-E053-F662850A8D1F","latestVersionIndicator":"Yes","beginDate":"2019-04-26","endDate":null,"createdBy":"SOKKERL","dateCreated":"2019-04-26","modifiedBy":"SOKKERL","dateModified":"2020-02-06","changeDescription":"4/26/19 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}